Advertisement
COCP vs SRPT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COCP is a StrongBuy and SRPT is a Hold.
COCP's RSI Indicator is sitting in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 50-day moving average for COCP moved above the 200-day moving average on October 05, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +5.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where COCP advanced for three days, in 167 of 200 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
COCP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COCP as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
COCP moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COCP crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COCP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for COCP entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. COCP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.363) is normal, around the industry mean (2.973). P/E Ratio (-1.255) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (45.249) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COCP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SRPT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for SRPT moved above the 200-day moving average on October 09, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for SRPT just turned positive on October 20, 2026. Looking at past instances where SRPT's MACD turned positive, the stock continued to rise in 31 of 46 cases over the following month. The odds of a continued upward trend are 67%.
Following a +12.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRPT advanced for three days, in 225 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 59 cases where SRPT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 80%.
The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SRPT as a result. In 66 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
SRPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SRPT crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
SRPT broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SRPT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.257) is normal, around the industry mean (2.973). P/E Ratio (-12.452) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (1.125) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. SRPT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
COCP | SRPT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 60 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 93 | |
PRICE GROWTH RATING 1..100 | 64 | 58 | |
P/E GROWTH RATING 1..100 | 42 | 97 | |
SEASONALITY SCORE 1..100 | n/a | 9 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SRPT's Valuation (13) in the Biotechnology industry is significantly better than the same rating for COCP (85) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew significantly faster than COCP’s over the last 12 months.
SRPT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as COCP (100) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to COCP’s over the last 12 months.
SRPT's SMR Rating (93) in the Biotechnology industry is in the same range as COCP (100) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to COCP’s over the last 12 months.
SRPT's Price Growth Rating (58) in the Biotechnology industry is in the same range as COCP (64) in the Pharmaceuticals Generic industry. This means that SRPT’s stock grew similarly to COCP’s over the last 12 months.
COCP's P/E Growth Rating (42) in the Pharmaceuticals Generic industry is somewhat better than the same rating for SRPT (97) in the Biotechnology industry. This means that COCP’s stock grew somewhat faster than SRPT’s over the last 12 months.
| COCP | SRPT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| Momentum ODDS (%) | 1 day ago 86% | 1 day ago 80% |
| MACD ODDS (%) | N/A | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 76% |
| Advances ODDS (%) | 25 days ago 83% | 3 days ago 77% |
| Declines ODDS (%) | 2 days ago 84% | 1 day ago 81% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 85% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COCP’s FA Score shows that 0 FA rating(s) are green while SRPT’s FA Score has 1 green FA rating(s).
- COCP’s FA Score: 0 green, 5 red.
- SRPT’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COCP’s TA Score shows that 5 TA indicator(s) are bullish while SRPT’s TA Score has 3 bullish TA indicator(s).
- COCP’s TA Score: 5 bullish, 5 bearish.
- SRPT’s TA Score: 3 bullish, 7 bearish.
Price Growth
COCP (@Biotechnology) experienced а -10.55% price change this week, while SRPT (@Biotechnology) price change was +2.19% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
COCP is expected to report earnings on Nov 13, 2026.
SRPT is expected to report earnings on Nov 02, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
COCP and
Correlation & Price change
A.I.dvisor tells us that COCP and SRPT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that COCP and SRPT's prices will move in lockstep.
| Ticker / NAME | Correlation To COCP | 1D Price Change % | ||
|---|---|---|---|---|
| COCP | 100% | +1.15% | ||
| SRPT - COCP | 30% Poorly correlated | -2.05% | ||
| TNXP - COCP | 28% Poorly correlated | -5.52% | ||
| BYSI - COCP | 28% Poorly correlated | -10.24% | ||
| NKTX - COCP | 27% Poorly correlated | -0.57% | ||
| CYTK - COCP | 27% Poorly correlated | -0.84% | ||
More | ||||